المؤلفون: Sara Del Tufo, Umberto Atripaldi, Antonella Nicastro, Iacopo Panarese, Davide Ciardiello, Valerio Nardone, Francesco Selvaggi, Roberto Grassi, Salvatore Cappabianca, Erika Martinelli, Alfonso Reginelli

المصدر: Radiology Case Reports, Vol 19, Iss 9, Pp 3626-3630 (2024)

مصطلحات موضوعية: Rectal cancer, Biomarkers, Perineural invasion, MRI, Staging, Medical physics. Medical radiology. Nuclear medicine, R895-920

الوصف: Treatment of rectal cancer has improved over the years thanks to a multidisciplinary approach. A correct staging has a fundamental role for risk stratification and to define the best treatment for each patient. Unfortunately, approximately 30% of patients with locally advanced rectal cancers will experience tumor recurrence. Thus, the identification of novel clinical-pathological and radiological prognostic factors represents an urgent unmet clinical need. Here we report the case of a patient with radically resected localized rectal cancer who developed an impressive early pelvic recurrence. To better understand the clinical scenario, we have studied the possible factors related to the aggressiveness of the disease. The only poor prognosticfactor that was evidenced at histological report was perineural invasion. Therefore, we questioned whether we could evaluate perineural invasion with imaging, similar to head and neck tumors. Learning from this clinical case, we believe that improving the risk stratification and radiology reporting is necessary to provide the best care for the patient and allow for a better prognosis prediction. Of course, our data should be considered as hypothesis generating and should be further investigated and validated in larger and prospective studies.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S193004332400428XTest; https://doaj.org/toc/1930-0433Test

الوصول الحر: https://doaj.org/article/eec5cbb29fdd4342a5a6cb660c4ec7b4Test

المؤلفون: Gianluca Arrichiello, Mario Pirozzi, Bianca Arianna Facchini, Sergio Facchini, Fernando Paragliola, Valeria Nacca, Antonella Nicastro, Maria Anna Canciello, Adele Orlando, Marianna Caterino, Davide Ciardiello, Carminia Maria Della Corte, Morena Fasano, Stefania Napolitano, Teresa Troiani, Fortunato Ciardiello, Giulia Martini, Erika Martinelli

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: colorectal cancer, tumor staging, lymph node metastases, adjuvant treatment, TNM, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Traditionally, lymph node metastases (LNM) evaluation is essential to the staging of colon cancer patients according to the TNM (tumor–node–metastasis) system. However, in recent years evidence has accumulated regarding the role of emerging pathological features, which could significantly impact the prognosis of colorectal cancer patients. Lymph Node Ratio (LNR) and Log Odds of Positive Lymph Nodes (LODDS) have been shown to predict patients’ prognosis more accurately than traditional nodal staging and it has been suggested that their implementation in existing classification could help stratify further patients with overlapping TNM stage. Tumor deposits (TD) are currently factored within the N1c category of the TNM classification in the absence of lymph node metastases. However, studies have shown that presence of TDs can affect patients’ survival regardless of LNM. Moreover, evidence suggest that presence of TDs should not be evaluated as dichotomic but rather as a quantitative variable. Extranodal extension (ENE) has been shown to correlate with presence of other adverse prognostic features and to impact survival of colorectal cancer patients. In this review we will describe current staging systems and prognostic/predictive factors in colorectal cancer and elaborate on available evidence supporting the implementation of LNR/LODDS, TDs and ENE evaluation in existing classification to improve prognosis estimation and patient selection for adjuvant treatment.

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2022.937114/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/c635368b544c4641a416a5d44b16752aTest

المؤلفون: Gianluca Arrichiello, Alessandra Perrone, Stefania Napolitano, Giulia Martini, Vincenzo De Falco, Pasquale Incoronato, Maria Maddalena Laterza, Gaetano Facchini, Vincenzo Famiglietti, Valeria Nacca, Fernando Paragliola, Rossella Napolitano, Gabriella Suarato, Antonella Nicastro, Erika Martinelli, Davide Ciardiello, Fortunato Ciardiello, Teresa Troiani

المساهمون: Arrichiello, Gianluca, Perrone, Alessandra, Napolitano, Stefania, Martini, Giulia, De Falco, Vincenzo, Incoronato, Pasquale, Laterza, Maria Maddalena, Facchini, Gaetano, Famiglietti, Vincenzo, Nacca, Valeria, Paragliola, Fernando, Napolitano, Rossella, Suarato, Gabriella, Nicastro, Antonella, Martinelli, Erika, Ciardiello, Davide, Ciardiello, Fortunato, Troiani, Teresa

المصدر: Targeted oncology. 17(6)

مصطلحات موضوعية: Male, Adult, Aged, 80 and over, Cancer Research, Antineoplastic Combined Chemotherapy Protocol, Colorectal Neoplasm, Middle Aged, Trifluridine, Bevacizumab, Oncology, Retrospective Studie, Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Pharmacology (medical), Female, Uracil, Colorectal Neoplasms, Human, Aged, Retrospective Studies

الوصف: Background The combination of trifluridine-tipiracil and bevacizumab was compared with trifluridine-tipiracil monotherapy in a randomized, open-label, phase II trial, resulting in a statistically significant and clinically relevant improvement in progression-free survival (PFS), with tolerable toxicity in patients with refractory metastatic colorectal cancer (mCRC); however, evidence supporting the role of this combination in a real-world setting is limited. Objective The aim of our work was to provide further evidence on the activity and safety of this combination in a real-world series of Western mCRC patients refractory or intolerant to previous therapies. Patient and Methods We conducted a retrospective, observational study of patients with mCRC refractory or intolerant to standard therapies. Patients were treated with trifluridine-tipiracil and bevacizumab. Previous therapy with fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab, aflibercept, regorafenib, and cetuximab or panitumumab (only RAS wild-type) was allowed, as was previous participation in clinical trials. Clinicopathological characteristics, overall response rate (ORR), disease control rate (DCR), overall survival (OS), PFS, and safety data were retrospectively collected and analyzed. Results We recorded 31 patients treated between 1 December 2017 and 30 June 2022. Median age was 69 years (range 38-82 years), 39% were male, 100% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1, tumor location was left-sided in 77% of cases, 54% had synchronous presentation, 35% were RAS mutant, 3% were BRAF mutant, and 71% underwent primary tumor resection; 64% of patients had liver metastases, 55% had lung metastases, and 23% had peritoneal carcinomatosis. The median number of previous treatment lines was 2 (range 0-5), and 84% of patients received at least one previous anti-angiogenic agent. The ORR and DCR were 3% and 71%, respectively. With a median follow-up of 8 months (range 2-39), median PFS was 6 months (95% confidence interval [CI] 3.1-8.9 months) and median OS was 14 months (95% CI 10.1-17.8 months). Adverse events of any grade were reported in 58% of patients. The most common grade 3-4 toxicities were neutropenia (19%) and anemia (6%); 35% of patients required either dose delays or dose reductions due to toxicity. Granulocyte colony-stimulating factor (G-CSF) prophylaxis was administered either on first or subsequent cycles of treatment in 35% of patients. No treatment-related deaths occurred. Sixty percent of the patients who discontinued treatment eventually received one or more lines of subsequent therapy. Conclusions Our series provides further evidence on the activity and safety of the combination of trifluridine-tipiracil and bevacizumab in a real-world series of Western refractory mCRC patients.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::260801518af82e7db771bf257d059bb5Test
https://pubmed.ncbi.nlm.nih.gov/36239883Test